The lease made to Seqirus Netherlands B.V. (hereinafter Seqirus) for the property located at Paasheuvelweg 28 in Amsterdam will become effective on 1 December 2018. For Seqirus, a global supplier of influenza vaccines, this will be its first laboratory space in the Netherlands. Together with the existing tenant, Huid Medisch Centrum, this property is now fully occupied.
Seqirus is leasing almost 1,400 m2 of space located on both the 2nd and 3rd floors which is currently being completely laid out and furnished according to the new tenant’s preferences. We started redeveloping these premises into a laboratory (ML1 and ML2 classes) and office space in mid-2016. The location is centrally located opposite the AMC hospital and readily accessible. This transaction was negotiated by Cushman & Wakefield.
Seqirus is part of CSL Limited (ASX:CSL), headquartered in Melbourne, Australia. The CSL Group of companies employs more than 20,000 people with operations in more than 60 countries.
Seqirus was established on 31 July 2015 following CSL’s acquisition of the Novartis influenza vaccines business and its subsequent integration with bioCSL. As one of the largest influenza vaccine providers in the world, Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness.
Seqirus operates state-of-the-art production facilities in the U.S., the UK and Australia, and manufactures influenza vaccines using both egg-based and cell-based technologies. It has leading R&D capabilities, Seqirus has a broad portfolio of differentiated products and a commercial presence in more than 20 countries.